Pre-existing atopy protects against a lethal respiratory viral infection in an ige independent fashion
Answers
Answer:During the 2009 influenza pandemic hospitalized asthma patients had lower mortality (4%) than those hospitalized without asthma (10%; p=0.04;BMC Infectious Diseases 2013,13:57), suggesting an atopic survival advantage. Using our well-characterized mouse model of paramyxoviral (Sendai virus, SeV) infection, we determined whether pre-existing atopy protects against lethal viral infection, and whether this requires IgE
Explanation:
Wild-type (WT) and IgE deficient (IgE-/-) B6 mice were sensitized and challenged with either ovalbumin (OVA; 40μg i.p. OVA/Alum 1:1, d1 and d7, then 30μg OVA i.n. daily d14-16), house dust mite (HDM; 1μg HDM i.n. d -5, then 10μg HDM i.n. daily d12-16), or PBS. All groups were inoculated with a lethal dose (2 x106pfu) of SeV and survival determined. In surviving mice, airway hyper-reactivity (AHR) and lung mucous cell metaplasia (MCM) was determined on d19-21 post-viral inoculation.